Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat gut cancers

NCT ID NCT06197178

Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells in the gut. The study included 17 adults with advanced colorectal, stomach, pancreatic, or small bowel cancers that had a specific marker (GCC). The main goals were to check safety, find the right dose, and see if the treatment could shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

17 people

The number who actually took part.

Started

Dec 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntary agreement to provide written informed consent. * Histologically confirmed metastatic colorectal cancers and other advanced gastrointestinal cancers (esophageal cancer, gastric cancer, pancreatic cancer, and small bowel cancer). * Aged 18 to 70 years, either sex. * GCC immunohistochemistry (IHC) staining is positive. * At least one measurable tumor lesion according to RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Expected survival ≥ 3 months. * Clinical laboratory values meet screening visit criteria. Exclusion Criteria: * Previous CAR-T cell, T cell receptor-engineered (TCR) T cell, or therapeutic tumor vaccination treatment within the past 6 months; and the corresponding CAR-T, TCR-T cells can still be detected. * Ever received any treatment targeting GCC. * Prior antitumor therapy with insufficient washout period. * Brain metastases. * Pregnant or lactating women. * Hepatitis C virus (HCV) antibody-positive or human immunodeficiency virus (HIV) antibody-positive, active syphilis, Epstein-Barr virus (EBV) infected. * Severe underlying disease. * Presence of other serious pre-existing medical conditions that may limit patient participation in the study.Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study. Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced gastrointestinal tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer digestive system cancer digestive system carcinoma esophageal cancer gastric cancer malignant pancreatic neoplasm small intestine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced gastrointestinal tumors

Contacts and locations

Locations

  • Beijing Cancer Hospital & Institute

    Beijing, Beijing Municipality, 100142, China

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, 102200, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.